Sophocarpine Alleviates Airway Epithelial Cell Inflammation in Asthma via Modulating the Cytokine- Cytokine Receptor and JAK2/STAT3 Signaling Pathways Authors: Wenbing Zhi, Hong Zhang, Ziyao Qiao, Shengnan Jiang, Zongsuo Liang, Yang Liu Published: 2026 ABSTRACT AbstractPurposeAsthma is a complex, heterogeneous, and inflammatory disease with an increasing incidence worldwide. This study aimed to investigate the therapeutic mechanisms of sophocarpine in asthma systematically.MethodsA house dust mite (HDM)-induced mouse and cell model was built. The effects and mechanisms of sophocarpine on asthma were evaluated in vivo and in vitro.ResultsIn the mouse model, sophocarpine treatment reduced airway pathological damage, mucus secretion, levels of interleukin (IL)-4, IL-5, IL-17, immunoglobulin E (IgE), and splenic index, as well as eosinophil accumulation. Network pharmacology studies revealed that sophocarpine may target TLR4, STAT3, and TNF, and regulates the JAK-STAT, and Viral protein interaction with cytokine and cytokine receptor signaling pathway et al. Docking results showed that the binding energy of sophocarpine to major targets varied from −7.55 to −5.22 kcal/mol. Transcriptome analysis identified 436 DEGs, which were enriched in pathways consistent with the network pharmacology, such as the JAK-STAT signaling pathway. We further confirmed that sophocarpine downregulated the mRNA expression levels of CCL5, CCL7, CCL12, CXCL1, CXCL2, CXCL3, CCR2, CXCR2, CXCR3, JAK2, STAT3, and c-MYC, and protein expression of CXCR2, JAK2, STAT3, and c-MYC in the mouse model. Sophocarpine also inhibited HDM-induced BEAS-2B cell viability decrease, cell apoptosis, and ROS overproduction, which was associated with modulation of the cytokine-cytokine receptor and JAK-STAT signaling pathways. Further, similar to sophocarpine, STAT3 inhibitors and siRNA effectively reduced the levels of STAT3, MYC, and CXCR2.ConclusionThese results indicate that sophocarpine effectively inhibits HDM-induced airway epithelial cell inflammation through regulating cytokine-cytokine receptor and JAK2/STAT3 signaling pathways.Keywords: asthma, airway epithelial cells, sophocarpine, cytokine-cytokine receptor and JAK2-STAT3 signaling pathways, transcriptomics Introduction Asthma is a chronic, heterogeneous inflammatory disease of the respiratory system that has emerged as one of the most prevalent respiratory conditions worldwide.1 According to the latest estimates from the Global Burden of Disease (GBD) study, more than 339 million people globally are currently affected by asthma, which accounts for a significant proportion of respiratory-related outpatient visits, hospitalizations, and premature mortality.2 In recent years, both the incidence and prevalence of asthma have exhibited a concerning upward trend globally, particularly within urbanized environments.3 Consequently, this escalating burden highlights an urgent and unmet need to elucidate the underlying pathogenesis of asthma and to develop novel, more effective therapeutic strategies. Asthma is characterized by persistent airway inflammation, orchestrated by a complex interplay of immune cells, inflammatory mediators, and signaling pathways and driven by a Type 2 immune response.4,5 Activated T helper 2 (Th2) cells secrete a spectrum of pro-inflammatory cytokines, specifically interleukin (IL)-4, IL-5, and IL-13, which facilitate the recruitment and activation of eosinophils, mast cells, and basophils to the airway mucosa.6 Crucially, research has identified eosinophilic infiltration in the airways induces airway epithelial injury, mucus hypersecretion, and airway hyperresponsiveness (AHR), thereby further exacerbating the severity of the condition.7 Airway epithelial cells serve as the primary physical barrier between the internal and external environments, playing a critical role in sensing allergens, initiating immune responses, and maintaining airway homeostasis.8 In recent years, airway epithelial cells are found not only act as a barrier to regulate airway homeostasis, but they have also been considered the initiators of airway inflammation, secreting epithelial-derived factors that promote the activation of various immune cells.9 In addition, epithelial characteristics are not just passive targets affected by immune cytokines (such as IL-4, and INF-γ), they are actually shaped directly by these surroundings.10 House dust mites (HDM) are one of the most common indoor allergens and are widely used to establish an asthma model, which recapitulates the key pathological features of human allergic asthma, including Th2 inflammatory cytokines, eosinophilic infiltration, mucus hypersecretion, and AHR.11 Despite the availability of various therapeutic agents for asthma, including inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs), and leukotriene modifiers, a significant proportion of patients still exhibit poor response to treatment or develop drug resistance.12,13 However, long-term use of inhaled corticosteroids may be associated with adverse effects, such as osteoporosis, metabolic disorders, and growth retardation in children.14–16 Therefore, there is an urgent need to explore novel, safe, and effective therapeutic candidates targeting airway epithelial cell injury for the treatment of asthma, as well as to elucidate their underlying molecular mechanisms. Sophocarpine (SPC), a quinolizidine alkaloid derived from a traditional Chinese herb Sophora flavescens Ait., has shown traditional employ in clearing heat and drying dampness, especially in various inflammatory diseases.17 Sophocarpine effectively suppressed tumor growth in xenograft models, modulated gut microbiota composition, and reduced the levels of inflammatory factors by regulating MAPK signaling pathway.18 Our previous study revealed the anti-asthmic effects using a OVA-induced mouse model.19 However, the efficacy and mechanisms of sophocarpine in asthma still lack systematic and mechanistic investigation. In recent years, the integration of network pharmacology and transcriptomics has emerged as a powerful tool for revealing the mechanisms of natural products.20 Therefore, this study aims to systematically evaluate the therapeutic potential of sophocarpine in asthma and elucidate its underlying mechanisms by constructing murine and cellular models, combined with network pharmacology, molecular docking, and transcriptomic analyses. This work is expected to provide experimental evidence supporting the development of sophocarpine as a novel therapeutic agent for asthma. Materials and Methods Reagents Sophocarpine (purity ≥ 98%, No.: 112,052–202001) obtained from National institutes for food and drug control (Beijing, China); House dust mite (HDM) extract (Dermatophagoides pteronyssinus, No.: XPB82D3A25) purchased from Stallergenes Greer (Lenoir, NC, USA); Mouse IL-4, IL-5, IL-17, and IgE enzyme-linked immunosorbent assay (ELISA) kits (No.: E-EL-M0043, E-EL-M0722, E-EL-M0047, E-EL-M3107) purchased from Elabscience Biotechnology Co., Ltd (Wuhan, China); Rabbit anti-mouse c-MYC (No.: ab32072) were purchased from Abcam (Cambridge, UK); Rabbit anti-mouse p-JAK2 (catalog No.: N13AU04), JAK2 (catalog No.: N24DE3P), STAT3 (No.: N29OC49), p-STAT3 (No.: N09JL08), CXCR2 (No.: 251676) primary antibodies were purchased from ZEN-BIOSCIENCE Co., Ltd (Sichuan, China); Annexin V-FITC/PI Apoptosis Detection Kit (No.: KGA107) was purchased from KeyGen Biotech Co., Ltd. (Nanjing, China); Reactive oxygen species (ROS) detection kit (No.: S0033) was obtained from Beyotime Biotechnology (Shanghai, China). Establishment of HDM-Induced Mouse Model and Experimental Grouping BALB/c mice (SPF female, weight 18~22 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The mice were housed in the SPF animal facility under controlled environmental conditions with free access to standard laboratory chow and sterile drinking water. A total of 40 mice were randomly divided into 4 groups using a random number table: Normal group, HDM- model group (HDM group), sophocarpine low-dose treatment group (20 mg/kg/d, SPC 20), and sophocarpine high-dose treatment group (40 mg/kg/d, SPC 40), with 10 mice in each group. On days 1, 2, 3, 8, 9, 10, 15, 16, and 17, the mice in the HDM group and sophocarpine treatment group were intranasally administered 50 μL of HDM extract solution. The mice in the normal group were intranasally administered 50 μL of saline. From day 11 to day 17, the mice in the sophocarpine low-dose treatment group and sophocarpine high-dose treatment group were administered sophocarpine at doses of 20 mg/kg and 40 mg/kg to evaluate the effect of interventions on established chronic inflammation, respectively. The normal group and the HDM group were administered an equal volume of saline. After the last challenge (day 17), the mice were fasted for 12 h and then sacrificed for subsequent experiments. All our animal studies were conducted in accordance with the Care and Use of Laboratory Animals (Northwest University Health Science Center, Xi’an, China), which was approved by the Animal Ethics Committee and the Institution Animal Care (License approval No.: NWU-IACUC-20250522M). Specimen Collection After the mice were anesthetized with pentobarbital, blood was taken and centrifuged at 2000 rpm for 10 min to collect serum. The bronchi and lungs were separated, and the left lung and upper airway were ligated. Saline (0.3 mL) was injected three times into the right lung with a syringe to obtain lavage fluid, which was then centrifuged at 2000 rpm for 5 minutes to obtain BALF and cell. The BALF supernatant was collected and stored at −80 °C for the detection of cytokines. The cell was resuspended in 200 μL of saline solution. Flow Cytometry For eosinophil counting, cells in BALF incubated with erythrocyte lysate, and stained with antibodies. The following antibodies were used for the eosinophil populations: eosinophils, CD11C-(percp690) CD170+(PE). All the antibodies used above were from eBioscience. Determination of Serum IgE and BALF Cytokine Levels The levels of IL-4, IL-5, and IL-17 in BALF supernatant and IgE in serum were detected using corresponding ELISA kits according to the manufacturers’ instructions. The absorbance (OD value) at 450 nm was measured using an microplate reader. Determination of Splenic Index After sacrificing the mice, the spleen was quickly isolated and removed, and the surface blood was blotted dry with filter paper. The wet weight of the spleen was measured using an electronic balance. The splenic index was calculated using the formula: Splenic index (mg/g) = Spleen wet weight (mg)/Mouse body weight (g). Histopathological Examination The same left lung lobe of each mouse was isolated and fixed in 4% paraformaldehyde solution for 48 h. After fixation, the lung tissue was dehydrated using a gradient of ethanol, cleared with xylene, and embedded in paraffin. Serial sections (5 μm thick) were cut using a pathological section machine. The sections were dewaxed with xylene and rehydrated through a gradient of ethanol before H&E staining and PAS staining. The histological quantification were performed in a fully blinded manner. RNA Extraction and Transcriptomic Analysis The left lung lobe tissues of six mice in the Normal group, HDM group, and SPC group (20 mg/kg/d) were collected, and lung tissue samples from six mice were randomly merged in pairs, resulting in a total of three samples per group for subsequent transcriptomic analysis. The total RNA was extracted using TRIzol reagent. The purity and integrity of RNA were evaluated using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific Inc., Waltham, MA, USA). Only RNA samples with an A260/A280 ratio between 1.8 and 2.0 and an RNA integrity number (RIN) ≥ 8.0 were used for transcriptomic analysis. The cDNA fragments were end-repaired, adenylated, and ligated with sequencing adapters. The ligated products were purified and amplified by PCR to generate the final cDNA library. The library quality was assessed using an Agilent 2100 Bioanalyzer, and the library was sequenced on an Illumina NovaSeq 6000 platform (Illumina, Inc., San Diego, CA, USA) to generate 150 bp paired-end reads. The expression of each transcript was calculated based on the transcripts per million reads (TPM) method. RSEM was used to quantify gene abundance. Differentially expressed genes (DEGs) between groups were identified with the criteria of |log2(fold change)| ≥ 1 and adjusted P-value < 0.05. Functional enrichment analysis of DEGs, including Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, was performed using clusterProfiler software (v4.2.2). The GO terms and KEGG pathways with adjusted P-value < 0.05 were considered significantly enriched. Quantitative Real-Time Polymerase Chain Reaction Validation Total RNA was extracted from lung tissues and BEAS-2B cells using TRIzol reagent, and cDNA was synthesized using the PrimeScript™ RT reagent Kit with gDNA Eraser. The reverse transcription reaction was performed using TB Green® Premix Ex Taq™ II on a StepOnePlus™ qPCR instrument. The qPCR was performed with CFX96 Real-Time PCR Detection System using the TB Green Premix Ex TaqTM (TaKaRa, Japan). Primers’ sequences were collected from published articles and validated by Primer-BLAST. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal reference gene. The relative expression levels of target genes were calculated using the 2−ΔΔCt method. The sequences of the primers used in this study are listed in Table 1. Table 1Gene Primer SequencesGeneSourceForward (5′-3′)Reverse (5′-3′)GAPDHHuman/MouseGGGTGTGAACCACGAGAAATACTGTGGTCATGAGCCCTTCCCL5Human/MouseTCATTGCTACTGCCCTCTGCGACAAAGACGACTGCTGGGTCCL7Human/MouseGCTTCTGTGTGTGCTGCTCTAACAGCTTCCCAGGGACACCCL12Human/MouseTAGCTACCACCATCAGTCCTCACACTGGCTGCTTGTGATTCCXCL1Human/MouseTAGGGTGAGGACATGTGTGGAAATGTCCAAGGGAAGCGTCXCL2Human/MouseCTCCTTTCCAGGTCAGTTAGCCAGAAGTCATAGCCACTCTCAACXCL3Human/MouseTGAGACCATCCAGAGCTTGACGCCTTGGGGGTTGAGGCAAACTTCCR2Human/MouseTGTCCACATCTCGTTCTCGGTTTAGATGGCCAGGTTGAGCAGGTAAATCXCR2Human/MouseGTTCTTTGCCCTGACCTTGCCTGTACTTGTGGCGTGGACGATCXCR3Human/MouseACATCAACTTCTACGCAGGGCACACAACAATGCAGGTGAGGJAK2Human/MouseGCTCTCACCAACATTACAGCTCCAACTTCTCTTCTTACACSTAT3Human/MouseCAGCAGCTTGACACACGGTAAAACACCAAAGTGGCATGTGAc-MYCHuman/MouseAATGAAAAGGCCCCCAAGGTAGTTATCGTCGTTTCCGCAACAAGTCCTCTTC Gene Primer Sequences Immunohistochemistry Staining The sections were treated with 3% hydrogen peroxide solution for 10 min at room temperature to block endogenous peroxidase activity, heated in citrate buffer using a microwave oven for 15 min for antigen retrieval, and then blocked with 5% bovine serum albumin (BSA) at 37 °C for 1 h. The primary antibodies against CXCR2 (1:200), p-JAK2 (1:150), p-STAT3 (1:150), and c-MYC (1:150) were added to the sections, which were incubated overnight at 4 °C. The next day, the sections were rinsed with PBS three times, and the HRP-conjugated secondary antibody (1:500) was added and incubated at 37 °C for 1 h. After rinsing with PBS, the sections were stained with 3,3′-diaminobenzidine (DAB) chromogen solution for 6 min and counterstained with hematoxylin solution for 1 min. After dehydration and clearing, the stained sections were observed under a light Olympus BX51 microscope. Network Pharmacology Analysis The potential targets of sophocarpine were predicted using multiple databases, including SwissTargetPrediction (http://www.swisstargetprediction.ch/),21 TCMSP (https://www.tcmsp-e.com/),22 and PharmMapper (http://www.lilab-ecust.cn/pharmmapper/),23 and collected from published articles. The targets related to asthma were collected from the GeneCards (https://www.genecards.org/),24 OMIM (https://omim.org/),25 DisGeNET (https://www.disgenet.org/), Drugbank (https://go.drugbank.com/), Therapeutic Target Database (https://ttd.idrblab.cn/),26 and PharmGKB (https://www.pharmgkb.org/) databases with the keyword “asthma”. The intersection targets between sophocarpine and asthma were considered as the potential therapeutic targets of sophocarpine for asthma by using Venny 2.1 software. The protein-protein interaction (PPI) network of the intersection targets was constructed using the STRING database (https://string-db.org/) with the species set to “Homo sapiens” and visualized using Cytoscape software (v3.9.1). GO functional enrichment analysis and KEGG pathway enrichment analysis of the intersection targets were performed using the clusterProfiler software (v4.2.2). The GO terms and KEGG pathways with adjusted P-value < 0.05 were considered significantly enriched. Molecular Docking The 3D structures of the core targets (IL-6, TNF, MAPK8, JAK2, JAK1, MAP2K1, STAT3, GSK3B, HSP90AA1, and TLR4) were downloaded from the RCSB PDB database (https://www.rcsb.org/) with the PDB IDs. The 3D structure of sophocarpine was drawn using ChemDraw software (v19.0). The target proteins and sophocarpine were processed using AutoDockTools software (v1.5.6), including adding hydrogen atoms, calculating charge, and setting rotatable bonds. The binding pocket of each target protein was defined based on the position of the original ligand. Docking performance was assessed by binding energy, and PyMOL software (v3.0.3) was used for visualization of the docking results. Cell Culture and Airway Epithelial Cell Injury Model Establishment The human bronchial epithelial cell line BEAS-2B was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM medium and were seeded into 96-well plates (1 × 105 cells/well) or 6-well plates (5 × 105 cells/well) and cultured for 24 h. The cells were divided into 4 groups: Normal group, HDM group, sophocarpine (20 μM) treatment group (spc 20 group), and sophocarpine (40 μM) treatment group (spc 40 group). The HDM group and spc-treatment groups were treated with 100 μg protein/mL HDM extract for 24h to induce cell damage, pretreated with or without sophocarpine, respectively. Cell Viability BEAS-2B cells were seeded into 96-well plates and inducedHDM with or without SPC. After 24 h of induction, 10 μL of CCK-8 solution was added to each well, and the plates were incubated in a cell incubator at 37 °C with 5% CO2 for 1 h. The absorbance (OD value) at 490 nm was measured using a microplate reader. The cell viability was calculated using the formula: Cell Viability (%) = Abs (Sample)/Abs (Control) × 100%. Detection of Cell Apoptosis by Flow Cytometry BEAS-2B cells were seeded into 6-well plates and treated. After 24 h of treatment, the cells were digested with 0.25% trypsin and collected by centrifugation at 1000 rpm for 5 min. The cell pellet was washed twice with PBS and stained with Annexin V-FITC and PI solution at room temperature in the dark for 20 min. The apoptosis rate was detected using a flow cytometer (Beckman, USA) within 1 h. Detection of ROS BEAS-2B cells were seeded into 6-well plates and treated. After 24 h of treatment, the cells were incubated with 10 μM DCFH-DA probe in a cell incubator at 37 °C with 5% CO2 for 20 min. The fluorescence intensity was detected using an Olympus BX51 microscope. Western Blotting Analysis Equal amounts of protein (30 μg) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% skimmed milk at room temperature for 1 h, and then incubated with primary antibodies overnight at 4 °C. The membranes were rinsed with TBST three times and incubated with HRP-conjugated secondary antibody (1:5000) at room temperature for 1 h. The protein bands were visualized using an enhanced chemiluminescence (ECL) detection kit and imaged with a chemiluminescence imaging system (Bio-Rad, XRS+, USA). The gray value of each protein band was analyzed using ImageJ software. Statistical Analysis All experimental data were expressed as mean ± standard deviation (mean ± SD). Statistical analysis was performed using GraphPad Prism software (version 9.0). One-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test was used to compare the differences between multiple groups. P < 0.05 was considered statistically significant. Results Sophocarpine Alleviates HDM-Induced Airway Pathological Damage in Asthma Mice H&E and PAS staining were used to observe the pathological changes of lung tissues in each group of mice. As shown in Figure 1A–C, the lung tissue structure of mice in the normal group was intact, with no obvious inflammatory cell infiltration and mucus production around the airways and blood vessels, and the airway epithelium was continuous and intact. HDM administration thickened the airway wall and increased inflammatory cells infiltrated and mucus production. In contrast, mice treated with sophocarpine reduced airway inflammation and mucus hypersecretion. Meanwhile, sophocarpine treatment decreased the concentrations of IL-4, IL-5, and IL-17 levels as well aseosinophilic and neutrophil infiltration in BALF (Figure 1D–F, I, and J). Specifically, the levels of serum IgE and the splenic index were significantly downregulated after treatment with sophocarpine (Figure 1G and H). Sophocarpine alleviates asthma in the HDM-induced mouse model. (A) H&E staining of lung tissues. (B) PAS staining of lung tissues. (C) Schematic diagram of the asthma mouse model establishment. (D–F) The levels of IL-5, IL-17, IL-4, in BALF. (G) The levels of IgE in serum. (H) Spleen index. (I) Proportion of eosinophils in BALF detected by flow cytometry. (J) Proportion of neutrophils in BALF detected by flow cytometry. Values are expressed as mean ± SD (n = 5).*p<0.05, compared with the normal group, **p<0.01, compared with the normal group; #p<0.05, compared with the HDM group, ##p<0.01, compared with the HDM group. Identification of Potential Targets of Sophocarpine Against Asthma by Network Pharmacology Analysis A total of 249 potential targets of sophocarpine and 8728 asthma-related targets were collected. Among the targets of sophocarpine and asthma, 140 common targets were identified as potential therapeutic targets of sophocarpine for asthma (Figure 2A). The PPI network of 140 common targets contained 140 nodes and 1508 edges. The results showed that the top 20 core targets included TNF, IL6, ALB, CASP3, STAT3, SRC, HSP90AA1, IFNG, IL10, MMP9, TLR4, ESR1, PPARG, PTEN, GSK3B, SIRT1, ICAM1, and JAK2 (Figure 2B). KEGG pathway enrichment analysis showed that the common targets were significantly enriched in 107 signaling pathways (P < 0.05), including Lipid and atherosclerosis, IL-17 signaling pathway, Chemokine signaling pathway, JAK-STAT signaling pathway, Viral protein interaction with cytokine and cytokine receptor, etc (Figure 2C). The network of “component-target-pathway” for sophocarpine in treating asthma was constructed and shown in Figure 2D, which contains 89 nodes (1 component node, 67 target nodes, 20 pathway nodes, and 1 disease node) and 317 edges. By sorting the degree values in descending order and performing topological analysis, the key targets of sophocarpine in the treatment of asthma were predicted as IL-6, TNF, MAPK8, JAK2, JAK1, MAP2K1, STAT3, GSK3B, HSP90AA1, and TLR4, and key signaling pathways including IL-17 signaling pathway, NOD-like receptor signaling pathway, chemokine signaling pathway, and JAK-STAT signaling pathway. Among them, proteins in cytokine-cytokine receptor interaction and their downstream JAK-STAT signaling pathway may be the core targets of sophocarpine against asthma. The network analysis of sophocarpine for the treatment of asthma. (A) Venn diagram. (B) Protein interaction analysis. (C) KEGG enrichment. The red box represents the key signaling pathways enriched in KEGG. (D) The network of “component-target-pathway”. Red circles represent drugs, blue squares represent targets, green diamonds represent signaling pathways, and yellow triangles represent diseases. (E) The autodocking results of sophocarpine with core targets, including IL-6, TNF, MAPK8, JAK2, JAK1, MAP2K1, STAT3, GSK3B, HSP90AA1, and TLR4. To further predict the binding affinity between sophocarpine and the core targets, we performed the Molecular docking. We selected the top 10 targets ranked by degree value in the network of “component-target-pathway” for molecular docking with sophocarpine. The receptor proteins corresponding to these core targets are IL-6 (PDBID: 1alu), TNF (PDBID: 5uui), MAPK8 (PDBID: 2xrw), JAK2 (PDBID: 8bxh), JAK1 (PDBID: 6n7a), MAP2K1 (PDBID: 3eqc), STAT3 (PDBID: 6njs), GSK3B (PDBID: 7sxj), HSP90AA1 (PDBID: 8x2r), and TLR4 (PDBID: 2z62). The binding sites of SPC with core targets were showed in Figure 2E. The docking results showed that sophocarpine had good binding affinity with all ten core targets, and the binding energy was between −7.55 kcal/mol and −5.22 kcal/mol (Table 2). Since the binding energy is less than −5 kcal/mol indicates a certain binding ability between the sophocarpinend the target protein, the results suggest that sophocarpine may stably bind to the ten core targets. Specifically, STAT3 has the strongest binding ability with sophocarpine with a binding energy of −7.55 kcal/mol. Table 2The Docking Results of SPC and Core TargetsNO.MoleculeProteinPDB IDBinding Energy (kcal/mol)BOXXYZ1SPCSTAT36njs−7.55−20.19917.17613.7222SPCJAK16n7a−7.37.416−17.10413.8453SPCMAPK82xrw−7.117.4166.5598.2274SPCTLR42z62−6.813.9880.1158.2765SPCHSP90AA18x2r−6.23−0.73814.68220.36SPCGSK3B7sxj−6.02−0.0514.07824.487SPCMAP2K13eqc−5.8−3.65441.21225.4518SPCJAK28bxh−5.6−2.25717.15520.8789SPCIL-61alu−5.36−0.0514.07824.4810SPCTNF5uui−5.2225.96734.92211.395 The Docking Results of SPC and Core Targets Transcriptomic Analysis Further Reveals the Regulatory Effect of Sophocarpine Using DESeq2 software with the criteria of |log2(fold change) | ≥ 1 and adjusted P < 0.05, a total of 2257 DEGs were identified between the HDM group and the Normal group, including 1538 upregulated genes and 719 downregulated genes (Figure 3A and C). Between the sophocarpine treatment group and the Model group, a total of 1110 DEGs were identified, including 681 upregulated genes and 429 downregulated genes. The intersection of these two sets of DEGs was 436, which were considered as DEGs regulated by sophocarpine in asthma mice (Figure 3B). KEGG pathway enrichment analysis showed that these DEGs were significantly enriched in viral protein interaction with cytokine and cytokine receptor, cytokine-cytokine receptor interaction, IL-17 signaling pathway, JAK-STAT signaling pathway, and other pathways, which was consistent with the results of network pharmacology (Figure 3D). Among them, the cytokine-cytokine receptor interaction pathway had the highest number of enriched genes. GO enrichment analysis showed that multiple targets enriched in BP terms, such as “positive regulation of cytokine-mediated signaling pathway”; CC terms such as “cytoplasm” and “cytokine production” (Figure 3E). Therefore, these results indicate that sophocarpine mainly regulates cytokine-cytokine receptor signaling pathway to exert anti-asthmatic effects. Transcriptome analysis. (A) Number of DEGs. (B) Venn diagram. (C) Volcano plot. Red and Yellow dots represent differentially expressed proteins (fold change >2 and p-value <0.05), while blue dots represent proteins without significant difference. (D) KEGG enrichment. (E) GO enrichment. The red box represents the key signaling pathways we focus on. Sophocarpine Regulated Key Genes Expression in Cytokine-Cytokine Receptor and JAK-STAT Signaling Pathways Various cytokines, growth factors, and other specific molecules activate JAK–STAT signaling to drive a range of physiological and pathological processes, such as proliferation, immune responses, inflammation, and malignancy.27,28 Based on the transcriptomic analysis results, key genes involved in the cytokine-cytokine receptor signaling pathway and JAK-STAT signaling pathway were selected for qPCR validation. The results showed that compared with the Normal group, the mRNA expression levels of CCL5, CCL7, CCL12, CXCL1, CXCL2, CXCL3, CCR2, CXCR2, CXCR3, JAK2, STAT3, and c-MYC in the HDM group were significantly upregulated (P < 0.01) (Figure 4A–L). After treatment with sophocarpine, the mRNA expression levels of these genes were significantly downregulated compared with the HDM group (Figure 4A–L). The qPCR results were consistent with the transcriptomic sequencing results, confirming the reliability of the sequencing data and the regulatory effect of sophocarpine on the cytokine-cytokine receptor signaling pathway and JAK-STAT signaling pathway at the transcriptional level. Sophocarpine treatment decreases the mRNA Levels of key genes in cytokine-cytokine receptor and JAK-STAT signaling pathways. (A–C) The mRNA levels of CCL5/7/12 in lung tissues. (D–F) The mRNA levels of CXCL1/2/3 in lung tissues. (G–I) The mRNA levels of CCR2 and CXCR2/3 in lung tissues. (J–L) The mRNA levels of JAK2, STAT3, and c-MYC in lung tissues. Values are expressed as mean ± SD (n = 3).**p<0.01, compared with the normal group; #p<0.05, compared with the HDM group, ##p<0.01, compared with the HDM group. Sophocarpine Downregulates the Expression of Key Proteins in Cytokine-Cytokine Receptor and JAK-STAT Signaling Pathways IHC staining in lung tissues showed that the positive staining of CXCR2, JAK2, STAT3, and c-MYC in the HDM group was significantly stronger than that in the Normal group (Figure 5A). Meanwhile, the protein expression of CXCR2, JAK2, STAT3, and c-MYC detected by Western blotting in the HDM group was significantly increased (Figure 5B). After treatment with sophocarpine, the positive staining intensity and expression of these proteins were significantly weakened (Figure 5A–F). These results indicate that sophocarpine downregulated the expression of key proteins in cytokine-cytokine receptor and JAK-STAT signaling pathways in the lung tissues of asthma mice. Sophocarpine regulates CXCR2/JAK/STAT signaling aix. (A) Immunostained CXCR2, p-JAK2, p-STAT3, and c-MYC in lung tissues. (B) The CXCR2, p-JAK2, JAK2, p-STAT3, STAT3, and c-MYC protein expressions in lung were measured by Western blotting. (C–F) Normalized quantitative data for c-MYC, CXCR2, p-JAK2, and p-STAT3 protein expressions. Values are expressed as mean ± SD (n = 3). **p<0.01, compared with the normal group; #p<0.05, compared with the HDM group, ##p<0.01, compared with the HDM group. Sophocarpine Inhibited HDM-Induced Airway Epithelial Cell Injury The airway epithelium serves as the first barrier to the external environment, secreting a large amount of cytokines that promote the development of asthma. CCK-8 results showed that HDM (10, 100, 200, 400, 800 μg protein/mL) significantly decreased the viability of BEAS-2B cells (Figure 6A). Thus, we selected 100 μM protein as a stimulus concentration for subsequent cell experiments. Sophocarpine (0~40 μM) does not affect the cell viability (Figure 6B). Compared with the HDM group, different concentrations of sophocarpine (20 or 40 μM) significantly increased the cell viability (Figure 6C), indicating that sophocarpine can effectively improve the viability of HDM-damaged airway epithelial cells. Furthermore, flow cytometry results showed that the apoptosis rate of the HDM group was significantly higher than that of the Normal group, while sophocarpine treatment significantly reduced the cell apoptosis rate (Figure 6D and E). In addition, sophocarpine treatment decreased the HDM-induced ROS overproduction (Figure 6F and G). These results showed that sophocarpine can effectively inhibit HDM-induced airway epithelial cell injury. Sophocarpine improves the HDM-induced airway epithelial cell injury. (A) The BEAS-2B cell viability induced by HDM. Data are pooled from 4 independent experiments. (B) The BEAS-2B cell viability by sophocarpine. Data are pooled from 4 independent experiments. (C) Sophocarpine treatment increased the BEAS-2B cell viability. (D) Annexin V/PI double staining to detect apoptosis of BEAS-2B cells. (E) The apoptotic ratio of BEAS-2B cells. (F) ROS levels. (G) The fluorescent quantitative analysis of ROS. Values are expressed as mean ± SD (n = 3). Data are pooled from 3 independent experiments).*p<0.05, compared with the normal group, **p<0.01, compared with the normal group; #p<0.05, compared with the HDM group, ##p<0.01, compared with the HDM group. Sophocarpine Downregulates the Secretion of Cytokines and JAK-STAT Signal Transduction in HDM-Induced BEAS-2B Cells To confirm whether sophocarpine downregulate cytokines secretion and JAK-STAT signal transduction in HDM-induced BEAS-2B cells to relieve asthma, we detected the mRNA and protein levels of CXCL1, CXCL2, CXCL3, CXCR2, JAK2, and STAT3 in BEAS-2B cells. The results showed that HDM increased the mRNA levels of CXCL1, CXCL2, CXCL3, CXCR2, JAK2, and STAT3 (Figure 7A–G), and the protein expression of CXCR2, JAK2, STAT3, and c-MYC (Figure 7H–L). Sophocarpine treatment significantly downregulated the secretion of these cytokines and blocked the phosphorylation of key protein expression in JAK-STAT signal transduction (Figure 7A–L). Sophocarpine regulates CXCR2/JAK/STAT signaling transduction in HDM-induced BEAS-2B cells. (A–G) The mRNA levels of CXCL1/2/3, CXCR2, JAK2, STAT3, and c-MYC. (H) The CXCR2, p-JAK2, JAK2, p-STAT3, STAT3, and c-MYC protein expressions in cells were measured by Western blotting. (I–L) Normalized quantitative data for c-MYC, CXCR2, p-JAK2, and p-STAT3 protein expressions. Values are expressed as mean ± SD (n = 3). Data are pooled from 3 independent experiments. *p<0.05, compared with the normal group, **p<0.01, compared with the normal group; #p<0.05, compared with the HDM group, ##p<0.01, compared with the HDM group. Further, STAT3 inhibitors (Stattic and S3i-201) treatment effectively reduced the mRNA levels of STAT3, MYC, and CXCR2 in HDM-stimulated BEAS-2B cells (Figure 8A–C). Protein–protein interaction result revealed that JAK2, STAT3, CXCR2, and MYC can interact with each other (Figure 8D). These findings suggest that these proteins may mutually influence one another, and are consistent with the results of STAT3 inhibitors. To further determine whether STAT3 is the key target of sophocarpine against asthma, we conducted siRNA knockdown experiments. Among the three STAT3 siRNA, the si-STAT3-149 efficiently suppressed STAT3 expression and attenuated the HDM-induced upregulation of CXCR2, MYC, and JAK2 mRNA in BEAS-2B cells (Figure 8E–I). Furthermore, the si-STAT3-149 inhibited the HDM-induced protein overexpreession of CXCR2, MYC, and JAK2 in BEAS-2B cells (Figure 8J–M). These results are consistent with the in vivo experimental results, revealingthat sophocarpine may regulatethe activation of cytokine-cytokine receptor and JAK-STAT signaling pathways and exerts a protective effect on the airway epithelium. STAT3 is core target in c-MYC/CXCR2/JAK signaling transduction in HDM-induced BEAS-2B cells. (A–C) The mRNA levels of CXCR2, JAK2, and c-MYC after STAT3 inhibitor treatment. Data are pooled from 4 independent experiments. (D) The PPI of STAT3, CXCR2, JAK2, and c-MYC. (E) The mRNA levels of STAT3 after STAT3 siRNA interference. (F–I) The mRNA levels of STAT3, c-MYC, CXCR2, and JAK2 in HDM-induced BEAS-2B cells. (J) CXCR2, p-JAK2, JAK2, and c-MYC protein expressions in cells were measured by Western blotting. (K–M) Normalized quantitative data for c-MYC, CXCR2, and p-JAK2 protein expressions. Values are expressed as mean ± SD (n = 3). Data are pooled from 3 independent experiments. *p<0.05, compared with the normal group, **p<0.01, compared with the normal group; #p<0.05, compared with the HDM group, ##p<0.01, compared with the HDM group. Discussion Asthma, a heterogeneous chronic inflammatory respiratory disease, poses an ongoing global public health challenge because of its complex pathophysiology and therapeutic variability.29 The exploration of novel active compounds becoming a key focus in anti-asthma drug research. In this study, the therapeutic potential of sophocarpine in asthma was systematically investigated through in vivo and in vitro experiments, integrated with network pharmacology, transcriptomics, and molecular biology techniques. We found that sophocarpine alleviated airway pathological damage, decreased the levels of IL-4, IL-5, and IL-17 and eosinophilic infiltration in BALF, and improved immune activation linked to serum IgE and splenic index. Furthermore, sophocarpine effectively regulated HDM-induced airway epithelial cell viability, apoptosis rate, and ROS overproduction. In the underlying mechanisms of action, the effects of sophocarpine are associated with cytokine-receptor-JAK-STAT signaling axis. Airway remodeling, chronic inflammation and mucus hypersecretion are three typical features of asthma, and these pathological changes directly lead to airway hyperreactivity and irreversible respiratory function damage.30,31 In vivo, HDM can accelerate airway epithelial shedding, inflammatory cell infiltration, and mucus overexpression.32 In this study, we found that sophocarpine treatment significantly reduced airway wall thickening, epithelial damage, mucus secretion, and inflammatory cell infiltration around airways. Mucus secretion is mainly regulated by Th2 cytokines such as IL-4 and IL-13, leading to goblet cell differentiation and mucin synthesis.33,34 The balance of pro-inflammatory and anti-inflammatory factors is crucial in the initiation and progression of asthma and airway homeostasis.35 IL-4 serves as aa core cytokine in driving T2 immune responses, promoting the proliferation and differentiation of B cells into plasma cells and thereby inducing the synthesis and secretion of IgE.36 The monoclonal antibody benralizumab targets the IL-5 receptor (IL-5R) via competitively blocking IL-5 binding, leading to substantially greater eosinophil reduction.37 Platycodin D decreased serum levels of IgE, IL-4, IL-5, IL-13, and IL-17A, and then alleviated airway inflammation and remodeling in OVA-induced asthmatic mice through regulating the EGFR/PI3K/Akt pathway.38 Here, we found that the inhibition of mucus secretion by sophocarpine is consistent with the downregulated levels of IL-4, IL-5, and IL-17 in BALF, as well as the reduction of serum IgE and splenic index, indicating that it may exert a regulatory effect on goblet cell function through suppressing Th2-type immune responses. Importantly, IL-5 is a specific cytokine, promoting the maturation, recruitment, and activation of eosinophils.39,40 Eosinophils infiltrate into the airway and release eosinophil cationic protein, major basic protein, and other toxic substances, which damage the airway epithelium and aggravate inflammation.41 We found that the HDM-induced accumulation of eosinophils in BALF was inhibited by sophocarpine. To further clarify the molecular mechanism of sophocarpine against, we performed network pharmacology, transcriptomics, and molecular docking. The potential therapeutic targets of Huanglian-Hongqu herb pair in ameliorating non-alcoholic fatty liver disease was revealed by integrating transcriptomics and network pharmacology.42 In our study, network pharmacology predicts that the core targets (including IL-6, TNF, MAPK8, JAK2, JAK1, MAP2K1, STAT3, GSK3B, HSP90AA1, and TLR4) and core pathways (including atherosclerosis signaling pathway, chemokine signaling pathway, and JAK-STAT signaling pathway, etc) of sophocarpine in treating asthma. Molecular docking results show that sophocarpine has good binding affinity with these targets (binding energy between −7.55 kcal/mol and −5.22 kcal/mol). Generally, the lower the binding energy, the stronger the binding force.43 The binding energy of sophocarpine with STAT3 is −7.55 kcal/mol, suggesting that it may directly bind to STAT3 and regulate its functions. Meanwhile, in this study, transcriptomics identified 436 DEGs. Functional enrichment analysis of network pharmacology and transcriptomics shows that sophocarpine mainly regulates cytokine-cytokine receptor interaction, JAK signaling pathway, and IL-17 signaling pathway, etc. Cytokine-cytokine receptor interaction and the JAK signaling pathway are closely related to the occurrence and development of asthma.44,45 Cytokine-cytokine receptor interaction is a central hub for transmitting inflammatory signals. A variety of pro-inflammatory cytokines (such as IL-4, IL-5, IL-17) and chemokines (CXCL1, CXCL2, CXCL3) in asthma bind to their corresponding receptors, activate intracellular signaling pathways, and regulate the expression of inflammatory genes.46,47 CXCL1/2/3 are cytokines belonging to the CXC sub-family of chemokines with CXC motif chemokine receptor 2 (CXCR2) as its main receptor.48 CXCL2 is primarily secreted by neutrophils.49 The CXCL1-CXCL2 heterodimer has been identified as a potent chemoattractant for neutrophils in asthma. Hu JQet al revealed that HDM accelerated airway inflammation and airway epithelial barrier disruption by regulating CXCL1 signaling.50 Here, we found that sophocarpine decreased the mRNA expression levels of chemokines, such as CXCL1, CXCL2, CXCL3, CCL5, CCL12, and their receptors, such as CCR2, CXCR2, and CXCR3, which may improve the airway inflammation. CCL12 is a mouse-specific chemokine with no human ortholog. Therefore, We focus primarily on human chemokines, such as CXCL1/2/3. The JAK signaling pathway is a key downstream pathway of cytokine-cytokine receptor interaction.51 After cytokines bind to their receptors, they induce the dimerization and phosphorylation of JAK, which further phosphorylates STAT, and the phosphorylated STAT translocates to the nucleus to regulate the transcription of target genes involved in inflammation and immune responses.52 Abnormal activation of the JAK-STAT signaling pathway is common in asthma, and JAK inhibitors have shown significant therapeutic effects in clinical trials of asthma.53 GDC-0214, an inhaled JAK inhibitor, decreased FeNO in mild asthma without evidence of systemic toxicity.53 Previous studies also demonstrated that HDM induces robust STAT3 activation in the airway epithelium. Accordingly, a STAT3 inhibitor (C188-9) suppressed lung inflammation, remodeling, and the accumulation of Th2 and Th17 cells in mouse models of asthma.54 Moreover, conditional deletion of STAT3 in the airway epithelium attenuated HDM-induced airway eosinophilia, Th2 cell accumulation, chemokine levels, and airway hyperresponsiveness to methacholine.55 Our study revealed that sophocarpine reduced the expression of key proteins in the JAK/STAT signaling pathway (including JAK2, STAT3, and c-MYC) in lung tissues. Therefore, these results indicate that sophocarpine may regulatethe activation of JAK/STAT signal transduction by targeting multiple upstream cytokines and receptors, thereby blocking the transcription of inflammatory genes and exerting anti-asthmatic effects. Airway epithelial cells are the first line of defense against external allergens, and their repeated damage by allergens is an important initiating event in the pathogenesis of asthma.9 The epithelium is not merely a passive structural target in inflammatory cascades, but an active, dynamic interface for immune regulation.56 Recent evidence indicates that the airway epithelium plays a central role in initiating type 2 immunity through the release of alarmins such as TSLP, IL-25, and IL-33.57 The phenotype of epithelial cells is profoundly shaped in return by neighboring infiltrating immune cells, forming a bidirectional crosstalk network.58 HDM extract, as a common allergen in the environment, can induce airway epithelial cell injury, leading to the secretion of pro-inflammatory cytokines, programmed cell death, and excessive oxidative stress.59 A VITAL study investigated that house dust mite sublingual allergen immunotherapy (HDM-SLIT) decreased IL-33 in patients with asthma.60 Thus, reducing the HDM-induced airway epithelial cell damage is an effective therapy for the treatment of asthma. In this study, we found that sophocarpine can significantly improve the HDM-induced BEAS-2B damage related to the increase of cell viability, reduction of the apoptosis rate, and inhibition of the overproduction of ROS. ROS that are not cleared in time can cause oxidative damage and amplify the inflammatory response.61 The scavenging effect of sophocarpine on ROS indicates that it may protect airway epithelial cells by inhibiting oxidative stress. Meanwhile, the inhibition of apoptosis by sophocarpine contribute to maintain the integrity of the airway epithelial barrier, and prevent allergens from entering the submucosa. In addition, we found that sophocarpine decreased the mRNA levels of CXCL1, CXCL2, CXCL3, CXCR2, JAK2, and STAT3, and the protein expression of CXCR2, JAK2, STAT3, and c-MYC. Importantly, these results are consistent with the effects of STAT3 inhibitors, and siRNA. Interestingly, we found that STAT3 silencing may attenuate JAK2 expression through a positive feedback loop, as JAK2 transcription is partly dependent on STAT3-mediated transcriptional activity.62 Additionally, cross-regulation within the JAK-STAT pathway, including STAT3-mediated positive feedback upregulation of JAK2 expression via inflammatory cytokine loops, may contribute to this observation.63 Therefore, all the results suggest that sophocarpine inhibits the activation of cytokine-cytokine receptor-JAK-STAT signaling axis and exerts a direct protective effect on the airway epithelium. Although in vitro experiments we have confirmed Sophocarpine’s direct anti-apoptotic and antioxidant effects on BEAS-2B cells, the observed alleviation of epithelial injury in vivo may stem from the suppression of the overall inflammatory microenvironment, indirectly reducing immune attack. In the future, we will focus on the epithelial protective effects in vivo and reveal the mechanism by which sophocarpine regulates epithelial cell function to alleviate asthma, combined with epithelial-specific gene knockout mice. Conclusion In summary, our study systematically demonstrates that sophocarpine exerts remarkable anti-asthma activity in vivo and in vitro. The mechanism of sophocarpine against asthma is related to the inhibition of airway inflammation, decrease in mucus secretion, and the partial regulation of cytokine-linked JAK2/STAT3 signaling pathways. Funding Statement This work was supported by the study of Project of Shaanxi Provincial Administration of Traditional Chinese Medicine (no.SZY-KJCYC-2025-ZY-005, no. SZY-KJCYC-2023-014, no.2025-CXTD-11), Innovation Capability Support Program of Shaanxi (2026RS-CXTD-53), Shaanxi Department of Science and Technology Project (No. 2022SF-183 and no. 2025SF-YBXM-495). Data Sharing Statement The data used to support the findings of this study are all provided. The data is provided on request from corresponding author (Yang Liu). Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors have no conflicts of interest. References Associated Data Data Availability Statement The data used to support the findings of this study are all provided. The data is provided on request from corresponding author (Yang Liu).